Document is current

Article History

Accepted: 19 March 2025

First Online: 7 April 2025

Competing interests

: B.P. reports honoraria for lectures from and participation on advisory boards for Adaptive Biotech, Amgen, Bristol Myers Squibb (BMS)/Celgene, Gilead, GSK, Janssen, Oncopeptides, Roche, Sanofi, Takeda and The Binding Site; has received unrestricted grants from BMS/Celgene, EngMab, GSK, Roche, Sanofi and Takeda; and has acted as a consultant for BMS/Celgene, Janssen and Sanofi. Q.S. reports consulting/advisory roles for AbbVie, BMS, Boehringer Ingelheim, Genmab, Hoosier Cancer Research Network, Kronos Bio, Mirati Therapeutics, Regeneron and Yiviva; speaker honoraria from Chugai Pharmaceutical; and research funding from BMS/Celgene, Janssen, MPAACT (to their institution), Novartis, Regeneron and Roche/Genentech. N.P. has received consultancy fees from Amgen, BMS/Celgene, Janssen and Takeda; research funding from Amgen, BMS/Celgene, Janssen and Takeda; and honoraria from Amgen, Celgene, Janssen, Takeda and The Binding Site. M.-T.C. has received honoraria from Amgen, Janssen and Sobi. A.O. has received consultancy and speaker fees from Amgen, BD Biosciences and BluePrint Medicines; and research support from BluePrint Medicines. B.G.M.D. reports consultancy roles for Amgen, BMS, Janssen and Takeda. N.C.M. reports consultancy or advisory roles for Adaptive Biotech, Amgen, BMS, Celgene, Janssen, Legend Biotech, Novartis, Pfizer and Takeda; has received honoraria or consultancy fees for serving on advisory boards from Takeda; and owns stock in Oncopep and DCT Pharmaceutical. J.S.-M. reports consulting or advisory roles for AbbVie, Amgen, BMS, Celgene, GSK, HaemaLogiX, Janssen, Karyopharm Therapeutics, MSD, Novartis, Regeneron, Roche, Sanofi, Secura Bio and Takeda.